VRDNViridian Therapeutics, Inc.

$2B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+203.9% YoY

Gross Profit

-$6M-283.8% margin

Operating Income

-$9M-406.1% margin

Net Income

-$9M-399.4% margin

EPS (Diluted)

$-4.31

QoQ Revenue Growth

-54.4%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$984,000

Balance Sheet

Total Assets

$82M

Total Liabilities

$14M

Stockholders' Equity

$68M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$718,000	+203.9%
Gross Profit	-$6M	-$5M	-29.9%
Operating Income	-$9M	-$7M	-20.6%
Net Income	-$9M	-$7M	-19.2%

Revenue Segments

Reimbursement Revenue

$1M51%

Collaboration Revenue

$1M49%

VRDN Q2 2018 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena